Anthony Cheung
Founder at ENGENE HOLDINGS INC.
Net worth: 2 M $ as of 2024-04-29
Profile
Anthony T.
Cheung is the founder of enGene Holdings, Inc. (founded in 2023) and currently holds the title of Chief Technology Officer.
Dr. Cheung is also the founder of enGene,.
Inc...
Dr. Cheung's education history includes an undergraduate degree from the University of British Columbia and a doctorate degree from Tulane University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ENGENE HOLDINGS INC.
0.23% | 2024-03-17 | 102,873 ( 0.23% ) | 2 M $ | 2024-04-29 |
Anthony Cheung active positions
| Companies | Position | Start |
|---|---|---|
| ENGENE HOLDINGS INC. | Founder | 2023-04-23 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Founder | - |
Training of Anthony Cheung
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Private companies | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Anthony Cheung
